From pioneering hearing research to developing new technologies for challenging medical conditions, the Bionics Institute marks 40 years of turning innovative ideas into potential solutions for patients.
Founded in 1986 by Professor Graeme Clark AC, the Bionics Institute was established to build on the success of the cochlear implant and advance research to improve outcomes for people with hearing loss. Four decades later, the Institute continues to pursue that vision, applying its expertise in medical device research and engineering to a broader range of health challenges.
Today, researchers at the Bionics Institute are developing innovative technologies and therapies for conditions including hearing loss, Parkinson’s disease, epilepsy, Crohn’s disease, rheumatoid arthritis and Alzheimer’s disease. This work spans early-stage research, device development and clinical trials, with the aim of translating promising discoveries into practical solutions that improve people’s lives.
The Institute’s impact extends beyond the laboratory. Collaboration with clinicians, universities, industry partners and supporters plays an important role in advancing research towards real-world applications. Commercialisation initiatives and spin-off companies, including Epiminder, EarGenie and Neo-Bionica, demonstrate how research developed at the Institute can progress towards clinical use.
As the Bionics Institute celebrates this milestone, it recognises the researchers, engineers, clinicians, partners, donors and supporters who have contributed to its work over the past 40 years.
To our supporters, thank you.
Your generosity, commitment and belief in our mission have helped make this research possible. Whether through philanthropy, collaboration or advocacy, your support helps our researchers pursue new ideas and bring promising technologies closer to the people who need them.
Looking ahead, the Institute remains focused on developing innovative medical devices and therapies to address unmet medical needs. With new research opportunities, growing partnerships and a strong foundation in medical device innovation, the next chapter will build on four decades of discovery and translation.
The goal remains unchanged: to transform lives by turning ambitious ideas into technologies that make a meaningful difference to human health.
